Kereos Inc.

A biopharmaceutical company with targeted nanoparticles for use with existing and new drugs for enhanced performance.

  • Stage Product In Development
  • Industry Biotechnology
  • Location St. Louis, MO, USA
  • Currency USD
  • Employees 5
  • Website kereos.com

Company Summary

Kereos is a biopharmaceutical company that has developed a nanoparticle drug delivery technology that enables targeted delivery of a broad range of therapeutic drug compounds, including existing drugs, new drug candidates and compounds that are too toxic or too fragile to be delivered without the protection and targeting offered by the Kereos technology.

Team

  • John Hefti
    EVP of Business Development and Strategic Planning

    Dr. Hefti is an experienced entrepreneur in both the life sciences and technology sectors. He has 14 issued US patents and 18 patent applications pending. Along with other senior management, he raised over $64M in venture investments for previous companies, and completed licensing deals worth over $300M. He studied mathematics and physics as an undergraduate (Columbia University) and graduate student (UC Berkeley), and has an MD from Stanford

  • John Hefti

Previous Investors

  • Prolog Ventures
    Unconfirmed
    Charter Life Sciences
    Unconfirmed
    MB Ventures
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free